Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 57.28
NLNK's Cash to Debt is ranked higher than
73% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. NLNK: 57.28 )
NLNK' s 10-Year Cash to Debt Range
Min: 0.79   Max: No Debt
Current: 57.28

Equity to Asset 0.82
NLNK's Equity to Asset is ranked higher than
84% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NLNK: 0.82 )
NLNK' s 10-Year Equity to Asset Range
Min: -5.11   Max: 0.87
Current: 0.82

-5.11
0.87
F-Score: 5
Z-Score: 37.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1081.27
NLNK's Operating margin (%) is ranked higher than
58% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. NLNK: -1081.27 )
NLNK' s 10-Year Operating margin (%) Range
Min: -2849.13   Max: -801.39
Current: -1081.27

-2849.13
-801.39
Net-margin (%) -880.09
NLNK's Net-margin (%) is ranked higher than
58% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. NLNK: -880.09 )
NLNK' s 10-Year Net-margin (%) Range
Min: -2852.7   Max: -779.85
Current: -880.09

-2852.7
-779.85
ROE (%) -48.77
NLNK's ROE (%) is ranked higher than
69% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. NLNK: -48.77 )
NLNK' s 10-Year ROE (%) Range
Min: -85.27   Max: -81.78
Current: -48.77

-85.27
-81.78
ROA (%) -40.69
NLNK's ROA (%) is ranked higher than
68% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. NLNK: -40.69 )
NLNK' s 10-Year ROA (%) Range
Min: -75.86   Max: -52.84
Current: -40.69

-75.86
-52.84
ROC (Joel Greenblatt) (%) -527.16
NLNK's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. NLNK: -527.16 )
NLNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -578.49   Max: -327.6
Current: -527.16

-578.49
-327.6
Revenue Growth (3Y)(%) -59.90
NLNK's Revenue Growth (3Y)(%) is ranked higher than
58% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. NLNK: -59.90 )
NLNK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -59.9
Current: -59.9

EBITDA Growth (3Y)(%) -37.10
NLNK's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NLNK: -37.10 )
NLNK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -37.1
Current: -37.1

EPS Growth (3Y)(%) -36.70
NLNK's EPS Growth (3Y)(%) is ranked higher than
59% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. NLNK: -36.70 )
NLNK' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -36.7
Current: -36.7

» NLNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

NLNK Guru Trades in Q4 2013

Jim Simons 28,200 sh (New)
Jean-Marie Eveillard 905,154 sh (+16.29%)
Jean-Marie Eveillard 2,000 sh (unchged)
Jean-Marie Eveillard 5,965 sh (unchged)
» More
Q1 2014

NLNK Guru Trades in Q1 2014

Jean-Marie Eveillard 1,161,805 sh (+28.35%)
Jean-Marie Eveillard 6,888 sh (unchged)
Jean-Marie Eveillard 3,285 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

NLNK Guru Trades in Q2 2014

Jean-Marie Eveillard 1,306,970 sh (+12.49%)
Jean-Marie Eveillard 7,147 sh (unchged)
» More
Q3 2014

NLNK Guru Trades in Q3 2014

Stanley Druckenmiller 182,500 sh (New)
Jean-Marie Eveillard 11,760 sh (unchged)
Jean-Marie Eveillard 1,257,619 sh (-3.78%)
» More
» Details

Insider Trades

Latest Guru Trades with NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Add 28.35%0.02%$21.38 - $50.4 $ 40.1119%1161805
Jean-Marie Eveillard 2013-09-30 Add 21.32%0.01%$15.78 - $20.08 $ 40.11125%778354
Jean-Marie Eveillard 2013-06-30 Add 95.04%0.02%$11.27 - $22.56 $ 40.11155%641554
Jean-Marie Eveillard 2013-03-31 New Buy0.01%$11.4 - $12.7 $ 40.11232%328939
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.90
NLNK's P/B is ranked higher than
62% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. NLNK: 14.90 )
NLNK' s 10-Year P/B Range
Min: 3.6   Max: 21.14
Current: 14.9

3.6
21.14
P/S 301.01
NLNK's P/S is ranked higher than
67% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. NLNK: 301.01 )
NLNK' s 10-Year P/S Range
Min: 14   Max: 1162.5
Current: 301.01

14
1162.5
EV-to-EBIT -24.98
NLNK's EV-to-EBIT is ranked higher than
68% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NLNK: -24.98 )
NLNK' s 10-Year EV-to-EBIT Range
Min: -36.7   Max: -2.8
Current: -24.98

-36.7
-2.8
Current Ratio 10.88
NLNK's Current Ratio is ranked higher than
88% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. NLNK: 10.88 )
NLNK' s 10-Year Current Ratio Range
Min: 0.97   Max: 23.49
Current: 10.88

0.97
23.49
Quick Ratio 10.88
NLNK's Quick Ratio is ranked higher than
88% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NLNK: 10.88 )
NLNK' s 10-Year Quick Ratio Range
Min: 0.97   Max: 23.49
Current: 10.88

0.97
23.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.08
NLNK's Price/Net Cash is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. NLNK: 20.08 )
NLNK' s 10-Year Price/Net Cash Range
Min: 4.76   Max: 25.51
Current: 20.08

4.76
25.51
Price/Net Current Asset Value 17.39
NLNK's Price/Net Current Asset Value is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. NLNK: 17.39 )
NLNK' s 10-Year Price/Net Current Asset Value Range
Min: 4.72   Max: 24.51
Current: 17.39

4.72
24.51
Price/Tangible Book 14.90
NLNK's Price/Tangible Book is ranked higher than
67% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. NLNK: 14.90 )
NLNK' s 10-Year Price/Tangible Book Range
Min: 3.93   Max: 14.71
Current: 14.9

3.93
14.71
Price/Median PS Value 1.39
NLNK's Price/Median PS Value is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. NLNK: 1.39 )
NLNK' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 3.41
Current: 1.39

0.07
3.41
Earnings Yield (Greenblatt) -4.00
NLNK's Earnings Yield (Greenblatt) is ranked higher than
77% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. NLNK: -4.00 )
NLNK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -4

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4NX.Germany,
NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The Company is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its products include biologic and small‑molecule immunotherapy product candidates intended to treat oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically‑resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The Company initiated this trial based on encouraging interim Phase 2 data that suggests improvement in both disease-free and overall survival. The Company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically‑resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator‑initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non‑patient specific) cells from previously established cell lines rather than cells derived from the patient. The Company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. Its strategy is to discover, develop and commercialize immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The Company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The Company is subject to federal, state, local and foreign regulation.
» More Articles for NLNK

Headlines

Articles On GuruFocus.com
NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

More From Other Websites
The Ebola Treatment You Haven't Heard Of Dec 19 2014
Human trial of experimental Merck Ebola vaccine is suspended Dec 11 2014
Ebola vaccine trial halted temporarily after joint pains -Geneva hospital Dec 11 2014
Ebola vaccine trial halted temporarily after joint pains -Geneva hospital Dec 11 2014
$300 mln pledged to buy Ebola vaccines as NewLink shot hits snag Dec 11 2014
$300 mln pledged to buy Ebola vaccines as NewLink shot hits snag Dec 11 2014
NewLink Genetics Sinks On Temporary Halt Of Ebola Trial Dec 11 2014
NewLink Ebola Shot Test Halted in Geneva on Side Effect Dec 11 2014
What We're Trading Dec 11 2014
One shot or two? Many questions unresolved in Ebola vaccine race Dec 11 2014
No serious side effects in Merck/Newlink Ebola vaccine test Dec 02 2014
No serious side effects in Merck/Newlink Ebola vaccine test Dec 02 2014
HTML PDF Dec 01 2014
American Airlines, Stone Energy, GlaxoSmithKline, Merck and NewLink Genetics highlighted as Zacks... Dec 01 2014
Canada to deploy military health staff to Sierra Leone in Ebola fight Nov 27 2014
Analyst: NewLink deal a 'boost' for Ebola vaccine Nov 26 2014
Merck buys rights to NewLink's experimental Ebola vaccine Nov 24 2014
Merck Obtains Rights to Ebola Vaccine Nov 24 2014
Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational... Nov 24 2014
Merck buys rights to NewLink's experimental Ebola vaccine Nov 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK